Addiction Pharmacology Lab, California Pacific Medical Center Research Institute, 3555 Cesar Chavez, San Francisco, CA 94110, USA.
Br J Sports Med. 2009 Oct;43(11):832-5. doi: 10.1136/bjsm.2008.048348. Epub 2008 Nov 3.
L-methamphetamine (the non-abused isomer of methamphetamine) is banned in athletic competition because it may improve athletic performance, but there are no studies assessing its effects on performance. In the United States L-methamphetamine is formulated in the non-prescription Vick's Vapor Inhaler (VVI) nasal decongestant. VVIs sold elsewhere (we used ones from the UK) contain similar inactive ingredients (menthol, camphor and Siberian pine oil) but no L-methamphetamine. This study tested the effects of inhaled L-methamphetamine delivered from a widely available non-prescription product on athletic performance.
In a 2-session double-blind placebo-controlled study 12 participants (ages 14-17) were dosed with 4 (session 1) and 12 (session 2) inhalations from VVIs with (USA) or without (UK) L-methamphetamine and then performed two 20 minute rides on a stationary bike with rides separated by a 30 minute rest.
The main outcome measure was miles travelled during each 20 minute ride. Secondary outcome measures included postride urine toxicology; heart rate and blood pressure before, 1, 5 and 10 minutes postride; energy, performance, endurance, and ability to breathe; and VVI preference. Data were analysed using Excel statistical macros.
After approximately 16 microg L-methamphetamine distance travelled was 5.26 (SD 0.53) miles vs 5.30 (0.55) with placebo; p = 0.81. After approximately 48 microg L-methamphetamine distance travelled was 5.30 (0.51) vs 5.35 (0.43) with placebo; p = 0.85. The approximately 16 microg dose increased systolic blood pressure from 72.6 (4.3) to 79.6 (6.6) mm Hg (p = 0.03) at 5 minutes postride but there were no other differences in outcomes.
Modest doses of inhaled L-methamphetamine probably do not improve athletic performance but do minimally raise diastolic blood pressure.
L-甲基苯丙胺(苯丙胺的非滥用异构体)在竞技比赛中被禁用,因为它可能会提高运动成绩,但目前尚无研究评估其对运动表现的影响。在美国,L-甲基苯丙胺被制成非处方 Vick's Vapor Inhaler(VVI)鼻减充血剂。在其他地方销售的 VVIs(我们使用的是来自英国的)含有类似的无活性成分(薄荷醇、樟脑和西伯利亚松油),但不含 L-甲基苯丙胺。本研究测试了从广泛使用的非处方产品中吸入 L-甲基苯丙胺对运动表现的影响。
在一项为期 2 期的双盲安慰剂对照研究中,12 名参与者(年龄 14-17 岁)分别接受了 4 次(第 1 期)和 12 次(第 2 期)来自 VVIs 的剂量,其中含有(美国)或不含有(英国)L-甲基苯丙胺,然后在固定自行车上进行两次 20 分钟的骑行,两次骑行之间间隔 30 分钟休息。
主要结果测量是每次 20 分钟骑行时行驶的英里数。次要结果测量包括骑行后的尿液毒理学;骑行前、1 分钟、5 分钟和 10 分钟时的心率和血压;能量、表现、耐力和呼吸能力;以及 VVI 偏好。数据使用 Excel 统计宏进行分析。
大约 16 微克 L-甲基苯丙胺后行驶的距离为 5.26(SD 0.53)英里,而安慰剂为 5.30(0.55)英里;p = 0.81。大约 48 微克 L-甲基苯丙胺后行驶的距离为 5.30(0.51)英里,而安慰剂为 5.35(0.43)英里;p = 0.85。大约 16 微克剂量使收缩压从 72.6(4.3)升高到 79.6(6.6)mmHg(p = 0.03),但在骑行后 5 分钟时没有其他结果差异。
吸入 L-甲基苯丙胺的适度剂量可能不会提高运动成绩,但会轻微升高舒张压。